Regulatory filings with the FDA are expected before the end of the year.
A combination of insulin glargine and the lixisenatide, a GLP-1 receptor agonist, showed superior results in helping patients with type 2 diabetes (T2D) control glycated hemoglobin (A1C) in a phase 3 trial, Sanofi reported today.
Sanofi released topline results of LixiLan-L, saying that the second pivotal trial for the drug combination met its primary endpoint. The study examined the efficacy and safety of a fixed-ratio combination of insulin glargine (Lantus), 100 units/mL, and lixisenatide versus treatment with insulin glargine 100 units/mL over a 30-week period. The study involved 736 patients with T2D whose A1C was not adequately controlled with basal insulin, either alone or in combination with 1 or 2 oral anti-diabetic agents. If patients were already taking metformin, that therapy was continued.
In July, Sanofi announced that the primary endpoint had been achieved in its first pivotal trial, LixiLan-O, which involved 1170 patients over a 30-week period. That trial involved patients whose T2D was not adequately controlled on metformin or metformin and another oral antidiabetic agent. In June, long-term cardiovascular (CV) results for lixisenatide were presented at the 75th Scientific Sessions of the American Diabetes Association, showing no CV risk or benefit.
In a statement, Sanofi said it expects to make regulatory submissions in the fourth quarter of 2015 with the FDA and in the first quarter of 2016 in Europe.
Exclusive Telemedicine Use Linked to Less Favorable Glycemic Outcomes for T2D Endocrinology Care
December 6th 2023Adults with type 2 diabetes (T2D) undergoing endocrinology care are more likely to experience less favorable hemoglobin A1c improvements if they only use telemedicine compared with patients using in-person care or a mix of both.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Study Reveals Factors That Further Increase Colorectal Cancer Risk for Adults With T2D
November 14th 2023The strongest associations between diabetes and colorectal cancer risk were observed in participants with a recent diabetes diagnosis and those who had not undergone recent colonoscopy, underscoring the significance of cancer screening.
Read More
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen